Evidence map›Paper›PMID 42660903›Full record

ArticleNature communications2026

Split intron-exon system for circular RNA synthesis.

Lei Wang, Qiaoli Zhai, Chunbo Dong, Weibing Zhang, Xu Ma, Kai Yang, Shaolong Qi, Yarong Wu, Guocan Yu, Lian-Qing Wang and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lei Wang *Department of Biopharmaceuticals, College of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China.
Qiaoli Zhai *Translational Medicine Center, Zibo Central Hospital, Zibo, China.ORCID 0000-0001-7685-3956
Chunbo Dong *State Key Laboratory of Natural Medicines, School of Biopharmacy, School of Elite Biomedical Engineers, China Pharmaceutical University, Nanjing, China.
Weibing ZhangShanxi Academy of Advanced Research and Innovation, Taiyuan, China.
Xu MaShanxi Academy of Advanced Research and Innovation, Taiyuan, China.
Kai YangKey Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, China.
Shaolong QiKey Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, China.
Yarong WuShanxi Academy of Advanced Research and Innovation, Taiyuan, China.
Guocan YuKey Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, China. guocanyu@mail.tsinghua.edu.cn.ORCID 0000-0003-1157-4184
Lian-Qing WangTranslational Medicine Center, Zibo Central Hospital, Zibo, China. lianqing.wang@hotmail.com.ORCID 0000-0002-7161-4718
George Fu GaoCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. gaof@im.ac.cn.ORCID 0000-0002-3869-615X
Zhida LiuState Key Laboratory of Natural Medicines, School of Biopharmacy, School of Elite Biomedical Engineers, China Pharmaceutical University, Nanjing, China. zhidaliu@cpu.edu.cn.ORCID 0000-0002-3980-8440

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82572597
6 · The paper itself

Abstract

Ribozyme-based approaches have been extensively employed for in vitro circular RNA (circRNA) synthesis. However, several critical challenges are impeding the progress in this field, including the relatively low ribozyme utilization efficiency, limited synthetic flexibility, and complicated downstream purification procedures. Here, we introduce a split intron-exon (SIE) system for circRNA synthesis by physically separating the ribozyme from its substrates. This design ensures efficient circRNA synthesis by overcoming the inherent limitations of current ribozyme-based techniques, in which each ribozyme can only catalyse the synthesis of at most one circRNA molecule. Moreover, the SIE system enables the efficient synthesis of both unmodified and chemically modified circRNAs. Furthermore, the recyclability and immobilization of the ribozyme within the SIE system reduce reaction impurities and improves circRNA enrichment and yield. Overall, the SIE system holds great potential to advance the diversification and large-scale development of circRNA therapeutics.

Indexed as

ExonsIntronsRNARNA, CatalyticRNA, CircularRNA SplicingRNARNA, CatalyticRNA, Circular

Identifiers

PMID42660903
PMCPMC13522490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.